While individuals with T2DM and coexistent cardiovascular disease are often receiving concurrent treatment with many of the abovementioned therapies, it is imperative that we more critically evaluate how their respective glucose-lowering medications (e.g. SGLT2 inhibitors, GLP-1R agonists) also impact the progression of ischemic heart disease. This evidence concerns the gene GLP1R and coronary artery disorder.